Skip to main navigation Skip to search Skip to main content

Personal profile

Personal webpage

Biography

Prof. Dr. Jürgen Kuball chairs the Department of Hematology at the UMC Utrecht Cancer Centre. Clinical activities focus around acute leukemia and allogeneic stem cell transplantation and he is medical director of the stem cell transplantation program. His research activities focus around tumor immunology and the ATMP development of a next generation of engineered immune cells. Within this context he was scientific co-founder of the UMC Utrecht spin-off company GADETA and holder of multiple patents dealing with engineered immune cells. Kuball is currently chair of the CTIWP of EBMT and also active member of the GoCART Secretary.

Dr. Kuball received his medical degree in Hematology at the University of Mainz, Germany, and completed his post-doctoral fellowship at the Fred Hutchinson Cancer Center in Seattle, WA, USA. He joined the Department of Hematology at the UMC Utrecht in 2007 as a hematologist and immunologist. In 2010, he became a VIDI-laureate, and the chair of the Applied & Tumor-Immunology section within the Laboratory of Translation Immunology. He has chaired the Department of Hematology (adults) since 2013.

For more information on experimental and translational research please visit Kuball Laboratories

Fellowship & awards

American Association of Cancer Research-GlaxoSmithKline Scholar in Cancer Research Award (2001)
Stipendiat der Deutschen Krebshilfe (2005-2007)
Team Science recognition award of the „Society for Immunotherapy of Cancer“ to Jürgen Kuball and the University of Washington, USA (2010)
VIDI-Laureate ZonMW, The Netherlands (2010)

External positions

Chair Cellular Therapy & Immunobiology Working Party (CTIWP) - Chair - EBMT

1 Apr 2026 → 31 Dec 3999

aandeelhouder - shareholder via Gadeta Founders - Century Therapeutics & Adeta

1 Jan 2024 → 31 Dec 3999

Chair - Chairing - Immunology Community Life Science

1 Jan 2023 → 31 Dec 3999

Secretary team member - bestuurslid - GoCART Coalition (EBMT/EHA)

1 Jan 2023 → 31 Dec 3999

Inkomsten licentie - Onderzoek - UMCU Holding

1 Jan 2022 → 31 Dec 3999

Commissie lid PPS commissie - grant indieningen voor KWF beoordelen - KWF

1 Jan 2022 → 31 Dec 3999

aandeelhouder - Receiving revenues from licensed patents via UMCU - UMC Holding

1 Jan 2021 → 31 Dec 3999

grant - grant ontvangen voor onderzoek - Novartis

1 Jan 2015 → 31 Dec 3999

Onderzoeker - grant ontvangen voor onderzoek - Miltenyi

1 Jan 2015 → 31 Dec 3999

Patent holder multipe inventions licensed to Gadeta-follow up company Century Therapeuitcs &Miltenyi - Patent houder - Various

1 Jan 2013 → 31 Dec 3999

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or